Peanut Allergy

Following receipt of increasing peanut oral immunotherapy, or home-measured peanut butter, desensitization to peanut protein in children initially able to ingest more than half a peanut was achieved, according to study results.

Researchers observed that only 8.3% of 24 children or adolescents with peanut allergy passed a double-blind placebo-controlled food challenge with at least 444 mg of peanut protein after receiving dupilumab for 24 weeks.

Regardless of sociodemographic or clinical characteristics, children with food allergy face a significant psychosocial burden, according to a survey of caregivers published in The Journal of Allergy and Clinical Immunology: In Practice.

Following receipt of dupilumab for 24 weeks, desensitization to peanut exposure in most children/adolescents with peanut allergy was not achieved, according to results published in Allergy.

Two-thirds of toddlers with peanut allergy who used the VIASKIN Peanut patch from DBV Technologies completed an oral food challenge at 36 months without meeting criteria for stopping, according to a webinar held by the company.

Although this year brought many advances in the treatment of food allergy, the FDA’s approval of omalizumab dominated our most popular coverage.

BOSTON — Caregivers can successfully introduce milk, egg and peanut to infants soon after beginning solid foods, according to a pair of posters at the American College of Allergy, Asthma & Immunology Annual Scientific Meeting.

Healio has compiled November’s most read news in asthma and allergy.

An expert at the American College of Allergy, Asthma & Immunology Annual Scientific Meeting addressed the fear surrounding oral food challenges in infants and toddlers and discussed why they should not be deferred.

IgGenix announced the first patient dosed with IGNX001, a monoclonal antibody-based therapeutic for peanut allergy.